Affimed NV
NASDAQ:AFMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Affimed NV
Cash from Financing Activities
Affimed NV
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Affimed NV
NASDAQ:AFMD
|
Cash from Financing Activities
€714k
|
CAGR 3-Years
-83%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-34%
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Cash from Financing Activities
-€52.9m
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Cash from Financing Activities
-€5.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Cash from Financing Activities
€97.4m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Cash from Financing Activities
-€40.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Formycon AG
XETRA:FYB
|
Cash from Financing Activities
€53.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
Affimed NV
Glance View
Affimed NV engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 187 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
See Also
What is Affimed NV's Cash from Financing Activities?
Cash from Financing Activities
714k
EUR
Based on the financial report for Sep 30, 2024, Affimed NV's Cash from Financing Activities amounts to 714k EUR.
What is Affimed NV's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-34%
The average annual Cash from Financing Activities growth rates for Affimed NV have been -83% over the past three years , and -34% over the past ten years .
